Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. / Carstensen, Helena; Hesselkilde, Eva Zander; Haugaard, Maria Mathilde; Flethøj, Mette; Carlson, Jonas; Pehrson, Steen; Jespersen, Thomas; Platonov, Pyotr G.; Buhl, Rikke.

In: Journal of cardiovascular electrophysiology, Vol. 30, No. 4, 2019, p. 596-606.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Carstensen, H, Hesselkilde, EZ, Haugaard, MM, Flethøj, M, Carlson, J, Pehrson, S, Jespersen, T, Platonov, PG & Buhl, R 2019, 'Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation', Journal of cardiovascular electrophysiology, vol. 30, no. 4, pp. 596-606. https://doi.org/10.1111/jce.13849

APA

Carstensen, H., Hesselkilde, E. Z., Haugaard, M. M., Flethøj, M., Carlson, J., Pehrson, S., Jespersen, T., Platonov, P. G., & Buhl, R. (2019). Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. Journal of cardiovascular electrophysiology, 30(4), 596-606. https://doi.org/10.1111/jce.13849

Vancouver

Carstensen H, Hesselkilde EZ, Haugaard MM, Flethøj M, Carlson J, Pehrson S et al. Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. Journal of cardiovascular electrophysiology. 2019;30(4):596-606. https://doi.org/10.1111/jce.13849

Author

Carstensen, Helena ; Hesselkilde, Eva Zander ; Haugaard, Maria Mathilde ; Flethøj, Mette ; Carlson, Jonas ; Pehrson, Steen ; Jespersen, Thomas ; Platonov, Pyotr G. ; Buhl, Rikke. / Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation. In: Journal of cardiovascular electrophysiology. 2019 ; Vol. 30, No. 4. pp. 596-606.

Bibtex

@article{97d59bf1c2414ae5b8131f6819aafb8e,
title = "Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation",
abstract = "Introduction: The atrial fibrillatory rate is a potential biomarker in the study of antiarrhythmic drug effects on atrial fibrillation (AF). The purpose of this study was to evaluate whether dose-dependent changes in the atrial fibrillatory rate can be monitored on surface electrocardiography (ECG) following treatment with dofetilide, ranolazine, and a combination of the two in an acute model of AF in horses. Methods and Results: Eight horses were subjected to pacing-induced AF on 4 separate days. Saline (control), dofetilide, ranolazine, or a combination of dofetilide and ranolazine was administered in four incremental doses. Atrial fibrillatory activity was extracted from surface ECGs using spatiotemporal QRST cancellation. The mean atrial fibrillatory rate before drug infusion was 297 ± 27 fpm. Dofetilide reduced the atrial fibrillatory rate following the infusion of low doses (0.89 µg/kg, P < 0.05) and within 5 minutes preceding cardioversion (P < 0.05). Cardioversion with ranolazine was preceded by a reduction in the atrial fibrillatory rate in the last minute (P < 0.05). The combination of drugs reduced the atrial fibrillatory rate in a similar manner to dofetilide used alone. A trend toward a lower atrial fibrillatory rate before drug infusion was found among horses cardioverting on low doses of the drugs. Conclusion: The atrial fibrillatory rate derived from surface ECGs showed a difference in the mode of action on AF between dofetilide and ranolazine. Dofetilide reduced the atrial fibrillatory rate, whereas ranolazine displayed a cardioverting mechanism that was distinct from a slowing of the fibrillatory process.",
keywords = "atrial fibrillation, atrial fibrillatory rate, combination therapy, dofetilide, ranolazine",
author = "Helena Carstensen and Hesselkilde, {Eva Zander} and Haugaard, {Maria Mathilde} and Mette Fleth{\o}j and Jonas Carlson and Steen Pehrson and Thomas Jespersen and Platonov, {Pyotr G.} and Rikke Buhl",
year = "2019",
doi = "10.1111/jce.13849",
language = "English",
volume = "30",
pages = "596--606",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Effects of dofetilide and ranolazine on atrial fibrillatory rate in a horse model of acutely induced atrial fibrillation

AU - Carstensen, Helena

AU - Hesselkilde, Eva Zander

AU - Haugaard, Maria Mathilde

AU - Flethøj, Mette

AU - Carlson, Jonas

AU - Pehrson, Steen

AU - Jespersen, Thomas

AU - Platonov, Pyotr G.

AU - Buhl, Rikke

PY - 2019

Y1 - 2019

N2 - Introduction: The atrial fibrillatory rate is a potential biomarker in the study of antiarrhythmic drug effects on atrial fibrillation (AF). The purpose of this study was to evaluate whether dose-dependent changes in the atrial fibrillatory rate can be monitored on surface electrocardiography (ECG) following treatment with dofetilide, ranolazine, and a combination of the two in an acute model of AF in horses. Methods and Results: Eight horses were subjected to pacing-induced AF on 4 separate days. Saline (control), dofetilide, ranolazine, or a combination of dofetilide and ranolazine was administered in four incremental doses. Atrial fibrillatory activity was extracted from surface ECGs using spatiotemporal QRST cancellation. The mean atrial fibrillatory rate before drug infusion was 297 ± 27 fpm. Dofetilide reduced the atrial fibrillatory rate following the infusion of low doses (0.89 µg/kg, P < 0.05) and within 5 minutes preceding cardioversion (P < 0.05). Cardioversion with ranolazine was preceded by a reduction in the atrial fibrillatory rate in the last minute (P < 0.05). The combination of drugs reduced the atrial fibrillatory rate in a similar manner to dofetilide used alone. A trend toward a lower atrial fibrillatory rate before drug infusion was found among horses cardioverting on low doses of the drugs. Conclusion: The atrial fibrillatory rate derived from surface ECGs showed a difference in the mode of action on AF between dofetilide and ranolazine. Dofetilide reduced the atrial fibrillatory rate, whereas ranolazine displayed a cardioverting mechanism that was distinct from a slowing of the fibrillatory process.

AB - Introduction: The atrial fibrillatory rate is a potential biomarker in the study of antiarrhythmic drug effects on atrial fibrillation (AF). The purpose of this study was to evaluate whether dose-dependent changes in the atrial fibrillatory rate can be monitored on surface electrocardiography (ECG) following treatment with dofetilide, ranolazine, and a combination of the two in an acute model of AF in horses. Methods and Results: Eight horses were subjected to pacing-induced AF on 4 separate days. Saline (control), dofetilide, ranolazine, or a combination of dofetilide and ranolazine was administered in four incremental doses. Atrial fibrillatory activity was extracted from surface ECGs using spatiotemporal QRST cancellation. The mean atrial fibrillatory rate before drug infusion was 297 ± 27 fpm. Dofetilide reduced the atrial fibrillatory rate following the infusion of low doses (0.89 µg/kg, P < 0.05) and within 5 minutes preceding cardioversion (P < 0.05). Cardioversion with ranolazine was preceded by a reduction in the atrial fibrillatory rate in the last minute (P < 0.05). The combination of drugs reduced the atrial fibrillatory rate in a similar manner to dofetilide used alone. A trend toward a lower atrial fibrillatory rate before drug infusion was found among horses cardioverting on low doses of the drugs. Conclusion: The atrial fibrillatory rate derived from surface ECGs showed a difference in the mode of action on AF between dofetilide and ranolazine. Dofetilide reduced the atrial fibrillatory rate, whereas ranolazine displayed a cardioverting mechanism that was distinct from a slowing of the fibrillatory process.

KW - atrial fibrillation

KW - atrial fibrillatory rate

KW - combination therapy

KW - dofetilide

KW - ranolazine

U2 - 10.1111/jce.13849

DO - 10.1111/jce.13849

M3 - Journal article

C2 - 30661267

AN - SCOPUS:85060757926

VL - 30

SP - 596

EP - 606

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 4

ER -

ID: 216924250